Previous studies showed that intermittent androgen deprivation
had prolonged the time between disease diagnosis and development of 'castrate-resistant' disease.
therapy (ADT), a common treatment for men with prostate cancer, reduces testosterone production and causes side effects that negatively impact quality of life and reduce physical functionality.
therapy: reduces levels of androgens in the body, slowing the growth of prostate cancers; achieved through orchiectomy, luteinizing hormone-releasing hormone analogs or antagonists, or antiandrogens
This finding suggests a reversal in the gene expression profile of androgen-refractory cancers that is caused by androgen deprivation
therapy, possibly by ligand-independent reactivation of AR, a mechanism that has been proposed by several authors.
It is not clear, however, if the same diagnostic and prognostic criteria should apply to prostate glands subjected to previous androgen deprivation
GTx is developing ACAPODENE[R] (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial evaluating toremifene citrate 80 mg for the treatment of serious side effects of androgen deprivation
therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial evaluating toremifene citrate 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN.
The lack of standardization of androgen deprivation
in this study (i.
These hot flashes data provide additional confirmation that the multiple estrogen related side effects of androgen deprivation
therapy for prostate cancer are treatable by toremifene citrate 80 mg, which binds to and selectively modulates the estrogen receptor depending on tissue type," said Mitchell S.
Combined androgen deprivation
therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
the Men's Health Biotech Company, announced that positive results of its Phase III interim analysis showing ACAPODENE(R) (toremifene citrate) in an 80 mg dose increased bone mineral density (BMD) in prostate cancer patients on androgen deprivation
therapy (ADT) are being presented today at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO).
Prostate cancer that cannot be cured may be held back by androgen deprivation
therapy (ADT), which prevents the male hormone testosterone fuelling tumours.
Improvements in bone mineral density in men with prostate cancer on androgen deprivation
are greatest in men who continue to receive alendronate therapy," Greenspan's group concludes.
the Men's Health Biotech Company, has announced the results of a lipid interim analysis of the pivotal Phase III ADT clinical trial evaluating oral, once daily ACAPODENE(R) (toremifene citrate) 80mg for the treatment of the multiple serious side effects of androgen deprivation
therapy (ADT) in men with advanced prostate cancer.
Food and Drug Administration (FDA) for the potential treatment of metastatic castration-resistant prostate cancer (CRPC), an advanced and difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of androgen deprivation
The Phase III Protocol of Androgen Suppression (AS) and 3DCTR/ IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer (RTOG 0521) trial (4) randomized 562 men with high-risk localized prostate cancer treated with radiation and two years of androgen deprivation
therapy (ADT), with and without the addition of adjuvant docetaxel (six cycles) and prednisone starting four weeks after radiation.